**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 88963

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma**

Chen JL *et al.* New biomarker for HCC

Jia-Li Chen, Lu Guo, Zhen-Ying Wu, Kun He, Han Li, Chi Yang, Yun-Wei Han

**Jia-Li Chen, Zhen-Ying Wu, Han Li, Yun-Wei Han,** Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China

**Lu Guo,** Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China

**Kun He,** Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China

**Chi Yang,** Department of Plastic Surgery, Meguiar's Medical Beauty Hospital, Chengdu 610000, Sichuan Province, China

**Co-first authors:** Jia-Li Chen and Lu Guo.

**Author contributions:** Chen JL, Guo L, and Han YW conceived, designed and refined the study protocol; Wu ZY, Li H, and Yang C were involved in the data collection; He K analyzed the data; Chen JL, and Guo L drafted the manuscript; all authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. Chen JL and Guo L contributed equally to this work. The reasons for designating Chen JL and Guo L as co-first authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-first authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-first authors best reflects this diversity. This also promotes the most comprehensive and in-depth examination of the research topic, ultimately enriching readers' understanding by offering various expert perspectives. Third, Chen JL and Guo L contributed efforts of equal substance throughout the research process. The choice of these researchers as co-first authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Chen JL and Guo L as co-first authors of is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.

**Corresponding author: Yun-Wei Han, MD, PhD, Professor, Researcher,** Department of Oncology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou 646000, Sichuan Province, China. lanpaoxiansheng@126.com

**Received:** October 16, 2023

**Revised:** December 6, 2023

**Accepted:** January 8, 2024

**Published online:** February 15, 2024

**Abstract**

BACKGROUND

Circulating tumor cell (CTC) count and neutrophil-to-lymphocyte ratio (NLR) are both closely associated with the prognosis of hepatocellular carcinoma (HCC).

AIM

To investigate the prognostic value of combining these two indicators in HCC.

METHODS

Clinical data were collected from patients with advanced HCC who received immune therapy combined with targeted therapy at the Department of Oncology, the Affiliated Hospital of Southwest Medical University, Sichuan, China, from 2021 to 2023. The optimal cutoff values for CTC programmed death-ligand 1 (PD-L1) (+) > 1 or CTC PD-L1 (+) ≤ 1 and NLR > 3.89 or NLR ≤ 3.89 were evaluated using X-Tile software. Patients were categorized into three groups based on CTC PD-L1 (+) counts and NLR: CTC-NLR (0), CTC-NLR (1), and CTC-NLR (2). The relationship between CTC-NLR and clinical variables as well as survival rates was assessed.

RESULTS

Patients with high CTC PD-L1 (+) expression or NLR at baseline had shorter median progression-free survival (mPFS) and median overall survival (mOS) than those with low levels of CTC PD-L1 (+) or NLR (*P* < 0.001). Meanwhile, patients in the CTC-NLR (2) group showed a significant decrease in mPFS and mOS. Cox regression analysis revealed that alpha-fetoprotein (AFP), CTC PD-L1 (+), and CTC-NLR were independent predictors of OS. The time-dependent receiver operating characteristic curve showed that the area under the curve of CTC-NLR at 12 months (0.821) and 18 months (0.821) was superior to that of AFP and CTC PD-L1 (+).

CONCLUSION

HCC patients with high CTC PD-L1 (+) or NLR expression tend to exhibit poor prognosis, and a high baseline CTC-NLR score may indicate low survival. CTC-NLR may serve as an effective prognostic indicator for patients with advanced HCC receiving immunotherapy combined with targeted therapy.

**Key Words:** Circulating tumor cells; Neutrophil–lymphocyte ratio; Hepatocellular carcinoma; Prognosis; Survival; Marker

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Chen JL, Guo L, Wu ZY, He K, Li H, Yang C, Han YW. Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma. *World J Gastrointest Oncol* 2024; 16(2): 372-385

**URL**: https://www.wjgnet.com/1948-5204/full/v16/i2/372.htm

**DOI**: https://dx.doi.org/10.4251/wjgo.v16.i2.372

**Core Tip:** This study evaluates whether the combination of programmed death-ligand 1 on circulating tumor cells (CTCs) and the neutrophil-lymphocyte ratio can serve as a biomarker for predicting the prognosis of immune combination targeted therapy in hepatocellular carcinoma. Our study suggests the combination of CTC and neutrophil-to-lymphocyte ratio (NLR) scores as a new index for predicting survival in patients with hepatocellular carcinoma (HCC). HCC patients may benefit from pre-treatment assessment of their CTC-NLR scores for risk classification and clinical decision-making.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and a major public health concern. The incidence rate of HCC has been soaring annually[1]. HCC is projected to become the third leading cause of cancer-related deaths by 2030[2]. Several treatment options are available for HCC, including liver transplantation, surgical resection, percutaneous ablation, radiotherapy, and arterial and systemic therapies[3]. Clinical physicians need to comprehensively evaluate the patient’s condition and adjust individualized treatment plans. Immune checkpoint inhibitor (ICI) monotherapy has provided significant clinical benefits to 15%-20% of patients since ICIs became available in clinical practice. ICIs have brought hope to many patients with malignant tumors. However, effective biomarkers for identifying this population are currently lacking[4,5]. Therefore, the identification of new predictive biomarkers to guide the selection of treatment plans is of great significance.

Currently, the diagnosis and treatment guidance for HCC patients primarily rely on imaging, tissue biopsy[6], and serum alpha-fetoprotein (AFP) levels[7,8]. However, tissue biopsy procedures are complicated, imaging tests lack diagnostic sensitivity, and AFP specificity is only about 80%[9,10], all of which cannot accurately reflect tumor heterogeneity and dynamically monitor tumor progression. Therefore, identifying a novel minimally invasive or non-invasive diagnostic strategy is urgent to monitor the therapeutic effects of HCC and predict prognosis.

In recent years, “liquid biopsy” technology has sparked strong interest from researchers[11,12]. Circulating tumor cells (CTCs) in liquid biopsies can provide information about abnormal protein expression, genomic mutations, and messenger RNA variations in solid tumors. They can also help understand the mechanisms underlying tumor occurrence, metastasis, and drug resistance from aspects such as cell morphology, migratory ability, and drug response[13,14]. Multiple studies have shown promising prospects of CTCs in the diagnosis, treatment, and prognosis guidance of various malignant tumors[15-18]. It has been demonstrated that programmed death-ligand 1 (PD-L1) expression is an essential biomarker for treatment decision-making in the era of immunotherapy. CTC PD-L1 expression can serve as an effective biomarker for clinical immunotherapy in various malignant tumors[19-21]. Meanwhile, several studies have shown that neutrophil-to-lymphocyte ratio (NLR) is a potential marker of tumor prognosis in certain malignant tumors[22-24]. In peripheral blood, CTCs can interact with inflammatory cells to induce systemic inflammation, promote metastasis, and worsen prognosis[25,26]. Considering NLR based on CTCs can improve risk stratification and optimize management in cancer patients[27]. It has been demonstrated that combining CTC with NLR can significantly improve the prognosis prediction of malignant gastrointestinal tumor patients[28]. Therefore, the present study explored the prognostic value of CTC PD-L1 (+) in combination with NLR in HCC patients receiving immunotherapy.

**MATERIALS AND METHODS**

***Patients***

Clinical data were collected from patients with advanced HCC who received immunotherapy in combination with targeted therapy at the Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, from 2021 to 2023. The inclusion criteria were as follows: (1) Pathologically diagnosed with HCC; (2) no previous anti-tumor treatment before admission; (3) Child-Pugh class A/B; (4) barcelona clinic liver cancer (BCLC) stage B/C; (5) received immunotherapy in combination with targeted therapy after admission. The exclusion criteria were as follows: (1) Patients with concomitant secondary primary malignancy; (2) intolerance to immune or targeted drugs during the tumor treatment process.

This study complied with the guidelines of the Helsinki Declaration. The research protocol was approved by the Clinical Trial Ethics Committee of the Affiliated Hospital of Southwest Medical University (approval number: KY2021063) and registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2100044198). All patients signed a written informed consent form before enrollment.

***Detection of CTC PD-L1 (+)***

Before treatment, 4 mL of peripheral blood was collected from each HCC patient using an anticoagulant tube and processed within 6 h. PD-L1 (+) CTCs were captured using the CytoSorter® circulating tumor cell sorter (Watson Biotech) and CytoNanoChip by combining anti‑epithelial cell adhesion molecule (Anti-EpCMA) Ab and anti-cell-surface vimentin (Anti-CSV) Ab with the CytoNanoChip and counted under a fluorescence microscope.

***Follow-up monitoring***

All patients underwent comprehensive baseline examinations, including imaging and laboratory tests, before treatment. Progression-free survival (PFS) was defined as the time from the start of treatment to disease progression or death, while overall survival (OS) was defined as the time from the start of treatment to death or last follow-up.

***Statistical analysis***

SPSS 26.0 (IBM, Chicago, IL, United States) and R version 4.2.2 were utilized for statistical analysis. Descriptive statistics were used to analyze patient baseline characteristics. X-Tile statistical package (version 3.6.1, Yale University, New Haven, CT, United States) was employed to calculate optimal cutoff points for CTC PD-L1 (+) and NLR, and the significance of between-group differences was evaluated using the chi-square test. Kaplan-Meier survival curves were compared using the log-rank test (Mantel-Cox). Univariate and multivariate Cox regression analyses were applied to investigate the association between patient baseline characteristics and OS. The area under the curve (AUC) was obtained by plotting the receiver operating characteristic (ROC) curve. A *P* value of < 0.05 was considered statistically significant.

**RESULTS**

***Patient characteristics***

A total of 124 patients with advanced HCC were recruited. The baseline characteristics of enrolled patients are shown in Table 1. The majority of the patients were males (90.3%), with a median age of 55 years (range 27-78 years). Seventy patients (56.5%) had hepatitis B virus (+), 46 (37.1%) had cirrhosis, 49 (39.5%) had serum AFP levels ≥ 400 ng/mL, 86 (69.4%) had multiple tumors, and 115 (92.7%) were in BCLC stage C.

***Correlation between CTC PD-L1 (+) and clinical variables and survival***

According to X-Tile software, the optimal cutoff value for CTC PD-L1 (+) was 1, and patients were divided into two categories based on this threshold. Among them, 68 patients (54.8%) had CTC PD-L1 (+) ≤ 1, while 56 patients (45.2%) had CTC PD-L1 (+) > 1. The relationship between CTC PD-L1 (+) and clinical variables is shown in Table 2. The results revealed that CTC PD-L1 (+) was associated with liver cirrhosis but not with other clinical variables.

Furthermore, the predictive significance of CTC PD-L1 (+) was examined between the two patient cohorts. It was found that patients with CTC PD-L1 (+) ≤ 1 had a longer median OS (mOS) [not reached (NR) *vs* 6.0 months, hazard ratio (HR) = 6.67, 95% confidence interval (95%CI): 3.60-12.37, *P* < 0.001, Figure 1A) and median PFS (mPFS, 7.8 months *vs* 3.2 months, HR = 3.59, 95%CI: 2.27-5.69, *P* < 0.001, Figure 1B) compared with those with CTC PD-L1 (+) > 1. Meanwhile, Kaplan-Meier curve analysis revealed that the 2-year OS rates for patients with high and low expression of CTC PD-L1 (+) were 22.6% and 69.0%, respectively.

***Relationship between NLR and clinical parameters and survival***

Based on the X-Tile software, the ideal cutoff value for NLR was 3.89. Patients were then classified into two groups based on this cutoff value, of which 67 (54.0%) patients had an NLR ≤ 3.89 and 57 (46.0%) patients had an NLR > 3.89. The relationship between NLR and clinical variables is displayed in Table 2. The results showed that NLR was significantly positively/negatively associated with cirrhosis, AFP, and PVTT but not with other clinical factors.

Additionally, the prognostic value of NLR was analyzed between the two groups and results revealed that patients with NLR ≤ 3.89 had longer mOS (NR *vs* 7.3 months, HR = 0.26, 95%CI: 0.14-0.47, *P* < 0.001, Figure 1C) and mPFS (7.8 months *vs* 3.3 months, HR = 0.31, 95%CI: 0.20-0.48, *P* <0.001, Figure 1D) compared with their counterparts. Moreover, Kaplan-Meier curve analysis showed that the 2-year OS rates of patients in the low and high NLR expression groups were 64.8% and 32.5%, respectively.

***Relationship between CTC-NLR and survival***

Based on the critical values of CTC PD-L1 (+) and NLR, the CTC-NLR score was calculated as follows: A score of 0 for CTC PD-L1 (+) ≤ 1 and NLR ≤ 3.89; a score of 1 for patients with CTC PD-L1 (+) > 1 or NLR > 3.89; and a score of 2 for CTC PD-L1 (+) > 1 and NLR > 3.89.

The NLR-CTC score was used to stratify patients for OS prediction. A total of 54 (43.5%) patients were categorized as CTC-NLR (0), 27 (21.8%) as CTC-NLR (1), and 43 (34.7%) as CTC-NLR (2) (Table 3). The results showed that CTC-NLR scores at baseline were associated with sex, alcohol consumption, and cirrhosis, independent of other clinical variables. Kaplan-Meier curve analysis showed that patients in the CTC-NLR (0) group performed well in terms of OS and PFS (*P* < 0.001), while those in the CTC-NLR (2) group performed worse (Figure 1D and E).

***Prognostic factors for OS***

Univariate Cox regression analysis revealed that cirrhosis, albumin bilirubin grade, AFP, CTC PD-L1 (+), NLR, and CTC-NLR were prognostic factors for OS (Table 4). These variables were then integrated into the multivariate Cox regression analysis. Because CTC PD-L1 (+), NLR, and CTC-NLR were highly correlated in this study, two independent multivariate models were constructed to eliminate multicollinearity between the three variables. Multivariate Cox regression analysis showed that CTC PD-L1 (+), CTC-NLR, and AFP were independent prognostic factors for OS (Table 5).

***Comparison of the predictive value of independent prognostic factors***

The prognostic efficacy of AFP, CTC PD-L1 (+), and CTC-NLR was compared at 6-, 12-, and 18-month OS using time-dependent ROC curves. The results revealed that the prognostic efficacy of CTC-NLR (0.821) was significantly better than that of CTC PD-L1 (+) (0.789) and AFP (0.687) at 12-month OS (Figure 2). The prognostic efficacy of CTC-NLR (0.821) was also remarkably better than that of CTC PD-L1 (+) (0.794) and AFP (0.676) at 18-month OS (Figure 2).

**DISCUSSION**

As the first line of defense of the organism, neutrophils play an important role in natural immunity. With technological advances in recent years, the complexity and heterogeneity of neutrophils in physiological and pathological states have received extensive attention. Numerous clinical studies have shown that neutrophils can promote tumorigenesis and progression in multiple ways, which significantly correlate with the patient’s prognosis. Cancer immunosurveillance relies heavily on lymphocytes, which can kill tumor cells[29,30]. NLR responds to a balanced relationship between tumor-validated states and anti-tumor immune responses[31]. Extensive studies have described NLR as a general prognostic factor for several cancer types[32-35]. The current study found that a high NLR was associated with poorer PFS and OS but was not an independent factor affecting the prognosis, which may be due to the insufficiently long follow-up time and large sample size in our study.

CTC is considered a source of tumor metastasis and recurrence[36]. The prognostic value of CTC has been demonstrated in breast, prostate, and colorectal cancer cancers, as well as small cell and non-small cell lung cancers[37-41]. Meanwhile, some studies have shown that CTC is an independent risk factor for HCC, which is significantly correlated with the prognosis of patients[42-44], and the CTC PD-L1 expression assay has a broad application prospect for dynamic monitoring of disease changes and evaluation of treatment response during immunotherapy[45-47]. These conclusions are consistent with our findings, in which high CTC expression of PD-L1 (+) at baseline was associated with poor prognosis in patients with HCC.

A combination of inflammatory index and CTC has been previously used to predict the outcome of malignant tumors[48,49]. Considering that NLR is strongly associated with tumor progression and CTC can predict prognosis, we combine NLR with CTC to predict the outcome of HCC. We evaluated the combined metric CTC-NLR and categorized patients into three groups based on their scores and discovered that patients with lower CTC-NLR scores had a survival benefit from the treatment. It was finally established that the three metrics, CTC-NLR, CTC PD-L1 (+), and AFP, were independent prognostic indicators for OS in patients with HCC. Meanwhile, CTC-NLR exhibited the highest time-dependent AUC at 12 and 18 months (*i.e.*, 0.821 for both). These findings demonstrated that a combination of CTC and NLR has a better prognostic value for HCC patients than CTC PD-L1 (+) or AFP alone. These data provide new avenues for risk stratification management of HCC.

Nonetheless, this study has several limitations. Firstly, this is a single center-based study. Secondly, because of the small sample size, we were unable to divide patients into training and validation cohorts. Finally, there was a relatively short follow-up period. Therefore, large-scale multicenter studies are warranted to validate and replicate our results.

**CONCLUSION**

In summary, the current study suggests the combination of CTC and NLR scores as a new index for predicting survival in patients with HCC. HCC patients may benefit from pre-treatment assessment of their CTC-NLR scores for risk classification and clinical decision-making.

**ARTICLE HIGHLIGHTS**

***Research background***

Patients with hepatocellular carcinoma (HCC) have a low benefit rate from immunotherapy. Clinical treatment lacks highly specific and sensitive prognostic biomarkers.

***Research motivation***

Investigation on whether the ratio of programmed death-ligand 1 (PD-L1) on circulating tumor cells (CTCs) combined with neutrophil-to-lymphocyte ratio (NLR) can serve as a biomarker for predicting the prognosis of immune combined targeted therapy in HCC.

***Research objectives***

Search for novel combined predictive biomarkers and apply them for risk stratification and clinical decision-making.

***Research methods***

This study adopts a method that combines clinical trials with data analysis.

***Research results***

HCC patients with high CTC PD-L1 (+) or NLR expression tend to exhibit poor prognosis, and a high baseline CTC-NLR score may indicate low survival.

***Research conclusions***

CTC-NLR may serve as an effective prognostic indicator for patients with advanced HCC receiving immunotherapy combined with targeted therapy.

***Research perspectives***

Future large-sample, multi-center studies are needed to further validate.

**ACKNOWLEDGEMENTS**

Thanks to Hangzhou Watson Biotech, Inc. (Hangzhou, China) for technical assistance. As well, we would like to thank the patients and their families for their contribution to the study.

**REFERENCES**

1 **Villanueva A**. Hepatocellular Carcinoma. *N Engl J Med* 2019; **380**: 1450-1462 [PMID: 30970190 DOI: 10.1056/NEJMra1713263]

2 **Rahib L**, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; **74**: 2913-2921 [PMID: 24840647 DOI: 10.1158/0008-5472.CAN-14-0155]

3 **Vogel A**, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. *Lancet* 2022; **400**: 1345-1362 [PMID: 36084663 DOI: 10.1016/S0140-6736(22)01200-4]

4 **Finn RS**, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. *J Clin Oncol* 2020; **38**: 193-202 [PMID: 31790344 DOI: 10.1200/JCO.19.01307]

5 **El-Khoueiry AB**, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; **389**: 2492-2502 [PMID: 28434648 DOI: 10.1016/S0140-6736(17)31046-2]

6 **Colombo F**, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M, Bertolini F, Rossi G, Mazzaferro V, Cadamuro M, Maggioni M, Agnelli L, Rebulla P, Prati D, Porretti L. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. *PLoS One* 2011; **6**: e21369 [PMID: 21731718 DOI: 10.1371/journal.pone.0021369]

7 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu**. Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236]. *J Hepatol* 2019; **70**: 817 [PMID: 30739718 DOI: 10.1016/j.jhep.2019.01.020]

8 **Marrero JA**, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; **68**: 723-750 [PMID: 29624699 DOI: 10.1002/hep.29913]

9 **Galle PR**, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. *Liver Int* 2019; **39**: 2214-2229 [PMID: 31436873 DOI: 10.1111/liv.14223]

10 **Forner A**, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018; **391**: 1301-1314 [PMID: 29307467 DOI: 10.1016/S0140-6736(18)30010-2]

11 **Alix-Panabières C**, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov* 2016; **6**: 479-491 [PMID: 26969689 DOI: 10.1158/2159-8290.CD-15-1483]

12 **Diaz LA Jr**, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol* 2014; **32**: 579-586 [PMID: 24449238 DOI: 10.1200/JCO.2012.45.2011]

13 **Heidrich I**, Ačkar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: Potential and challenges. *Int J Cancer* 2021; **148**: 528-545 [PMID: 32683679 DOI: 10.1002/ijc.33217]

14 **Hurtado P**, Martínez-Pena I, Piñeiro R. Dangerous Liaisons: Circulating Tumor Cells (CTCs) and Cancer-Associated Fibroblasts (CAFs). *Cancers (Basel)* 2020; **12** [PMID: 33027902 DOI: 10.3390/cancers12102861]

15 **Riethdorf S**, O'Flaherty L, Hille C, Pantel K. Clinical applications of the CellSearch platform in cancer patients. *Adv Drug Deliv Rev* 2018; **125**: 102-121 [PMID: 29355669 DOI: 10.1016/j.addr.2018.01.011]

16 **Chen W**, Zhang J, Huang L, Chen L, Zhou Y, Tang D, Xie Y, Wang H, Huang C. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer. *Clin Breast Cancer* 2019; **19**: e239-e246 [PMID: 30472074 DOI: 10.1016/j.clbc.2018.10.009]

17 **Tamminga M**, de Wit S, van de Wauwer C, van den Bos H, Swennenhuis JF, Klinkenberg TJ, Hiltermann TJN, Andree KC, Spierings DCJ, Lansdorp PM, van den Berg A, Timens W, Terstappen LWMM, Groen HJM. Analysis of Released Circulating Tumor Cells During Surgery for Non-Small Cell Lung Cancer. *Clin Cancer Res* 2020; **26**: 1656-1666 [PMID: 31772122 DOI: 10.1158/1078-0432.CCR-19-2541]

18 **Pantel K**, Hille C, Scher HI. Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. *Clin Chem* 2019; **65**: 87-99 [PMID: 30602476 DOI: 10.1373/clinchem.2018.287102]

19 **Ilié M**, Szafer-Glusman E, Hofman V, Chamorey E, Lalvée S, Selva E, Leroy S, Marquette CH, Kowanetz M, Hedge P, Punnoose E, Hofman P. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. *Ann Oncol* 2018; **29**: 193-199 [PMID: 29361135 DOI: 10.1093/annonc/mdx636]

20 **Tan Z**, Yue C, Ji S, Zhao C, Jia R, Zhang Y, Liu R, Li D, Yu Q, Li P, Hu Z, Yang Y, Xu J. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. *Oncologist* 2021; **26**: e2227-e2238 [PMID: 34516729 DOI: 10.1002/onco.13981]

21 **Khattak MA**, Reid A, Freeman J, Pereira M, McEvoy A, Lo J, Frank MH, Meniawy T, Didan A, Spencer I, Amanuel B, Millward M, Ziman M, Gray E. PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. *Oncologist* 2020; **25**: e520-e527 [PMID: 32162809 DOI: 10.1634/theoncologist.2019-0557]

22 **Sun Y**, Zhang Y, Huang Z, Lin H, Lu X, Huang Y, Chi P. Combination of Preoperative Plasma Fibrinogen and Neutrophil-to-Lymphocyte Ratio (the F-NLR Score) as a Prognostic Marker of Locally Advanced Rectal Cancer Following Preoperative Chemoradiotherapy. *World J Surg* 2020; **44**: 1975-1984 [PMID: 32020327 DOI: 10.1007/s00268-020-05407-3]

23 **Walsh SR**, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. *J Surg Oncol* 2005; **91**: 181-184 [PMID: 16118772 DOI: 10.1002/jso.20329]

24 **Guo W**, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. *Cancer Med* 2019; **8**: 4135-4148 [PMID: 31197958 DOI: 10.1002/cam4.2281]

25 **Szczerba BM**, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R, Singer J, Beisel C, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Beerenwinkel N, Aceto N. Neutrophils escort circulating tumour cells to enable cell cycle progression. *Nature* 2019; **566**: 553-557 [PMID: 30728496 DOI: 10.1038/s41586-019-0915-y]

26 **Luo Q**, Wang C, Peng B, Pu X, Cai L, Liao H, Chen K, Zhang C, Cheng Y, Pan M. Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma. *Front Oncol* 2020; **10**: 1758 [PMID: 33224869 DOI: 10.3389/fonc.2020.01758]

27 **Chong W**, Zhang Z, Luo R, Gu J, Lin J, Wei Q, Li B, Myers R, Lu-Yao G, Kelly WK, Wang C, Yang H. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. *BMC Cancer* 2021; **21**: 655 [PMID: 34078304 DOI: 10.1186/s12885-021-08405-3]

28 **Qian C**, Cai R, Zhang W, Wang J, Hu X, Zhang Y, Jiang B, Yuan H, Liu F. Neutrophil-Lymphocyte Ratio and Circulating Tumor Cells Counts Predict Prognosis in Gastrointestinal Cancer Patients. *Front Oncol* 2021; **11**: 710704 [PMID: 34307180 DOI: 10.3389/fonc.2021.710704]

29 **Szilasi Z**, Jósa V, Zrubka Z, Mezei T, Vass T, Merkel K, Helfferich F, Baranyai Z. Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Markers of Survival in Patients with Head and Neck Tumours-Results of a Retrospective Multicentric Study. *Int J Environ Res Public Health* 2020; **17** [PMID: 32155982 DOI: 10.3390/ijerph17051742]

30 **De Giorgi U**, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. *Clin Breast Cancer* 2012; **12**: 264-269 [PMID: 22591634 DOI: 10.1016/j.clbc.2012.04.004]

31 **Valero C**, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, Long Roche KC, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. *Nat Commun* 2021; **12**: 729 [PMID: 33526794 DOI: 10.1038/s41467-021-20935-9]

32 **Stotz M**, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. *Br J Cancer* 2013; **109**: 416-421 [PMID: 23799847 DOI: 10.1038/bjc.2013.332]

33 **Templeton AJ**, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014; **106**: dju124 [PMID: 24875653 DOI: 10.1093/jnci/dju124]

34 **Guthrie GJ**, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. *Crit Rev Oncol Hematol* 2013; **88**: 218-230 [PMID: 23602134 DOI: 10.1016/j.critrevonc.2013.03.010]

35 **Valero C**, Zanoni DK, McGill MR, Ganly I, Morris LGT, Quer M, Shah JP, Wong RJ, León X, Patel SG. Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. *Cancer* 2020; **126**: 994-1003 [PMID: 31809562 DOI: 10.1002/cncr.32591]

36 **Ring A**, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology, vulnerabilities and clinical applications of circulating tumour cells. *Nat Rev Cancer* 2023; **23**: 95-111 [PMID: 36494603 DOI: 10.1038/s41568-022-00536-4]

37 **Allard WJ**, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004; **10**: 6897-6904 [PMID: 15501967 DOI: 10.1158/1078-0432.CCR-04-0378]

38 **Cristofanilli M**, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004; **351**: 781-791 [PMID: 15317891 DOI: 10.1056/NEJMoa040766]

39 **Hou JM**, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. *J Clin Oncol* 2012; **30**: 525-532 [PMID: 22253462 DOI: 10.1200/JCO.2010.33.3716]

40 **Aggarwal C**, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Cohen SJ. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. *Ann Oncol* 2013; **24**: 420-428 [PMID: 23028040 DOI: 10.1093/annonc/mds336]

41 **Scher HI**, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. *Lancet Oncol* 2009; **10**: 233-239 [PMID: 19213602 DOI: 10.1016/S1470-2045(08)70340-1]

42 **Kelley RK**, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. *BMC Cancer* 2015; **15**: 206 [PMID: 25884197 DOI: 10.1186/s12885-015-1195-z]

43 **Ye X**, Li G, Han C, Han Q, Shang L, Su H, Han B, Gong Y, Lu G, Peng T. Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma. *Cancer Manag Res* 2018; **10**: 5639-5647 [PMID: 30532586 DOI: 10.2147/CMAR.S175489]

44 **Ha Y**, Kim TH, Shim JE, Yoon S, Jun MJ, Cho YH, Lee HC. Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study. *Hepatol Int* 2019; **13**: 726-735 [PMID: 31691073 DOI: 10.1007/s12072-019-09994-9]

45 **Yue C**, Jiang Y, Li P, Wang Y, Xue J, Li N, Li D, Wang R, Dang Y, Hu Z, Yang Y, Xu J. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. *Oncoimmunology* 2018; **7**: e1438111 [PMID: 29900038 DOI: 10.1080/2162402X.2018.1438111]

46 **Bergmann S**, Coym A, Ott L, Soave A, Rink M, Janning M, Stoupiec M, Coith C, Peine S, von Amsberg G, Pantel K, Riethdorf S. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). *Oncoimmunology* 2020; **9**: 1738798 [PMID: 32391189 DOI: 10.1080/2162402X.2020.1738798]

47 **Guibert N**, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, Mourlanette J, Gouin S, Dormoy I, Favre G, Mazieres J, Pradines A. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. *Lung Cancer* 2018; **120**: 108-112 [PMID: 29748004 DOI: 10.1016/j.lungcan.2018.04.001]

48 **De Giorgi U**, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, Alvarez RH, Ueno NT, Cristofanilli M, Reuben JM. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. *Ther Adv Med Oncol* 2019; **11**: 1758835919866065 [PMID: 31452692 DOI: 10.1177/1758835919866065]

49 **Hu B**, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res* 2014; **20**: 6212-6222 [PMID: 25271081 DOI: 10.1158/1078-0432.CCR-14-0442]

**Footnotes**

**Institutional review board statement:** This study complied with the guidelines of the Helsinki Declaration. The research protocol was approved by the Clinical Trial Ethics Committee of the Affiliated Hospital of Southwest Medical University (approval number: KY2021063) and registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2100044198).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All authors have nothing to disclose.

**Data sharing statement:** The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 16, 2023

**First decision:** December 6, 2023

**Article in press:** January 8, 2024

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0


**P-Reviewer:** Nwabo Kamdje AH, Cameroon **S-Editor:** Lin C **L-Editor:** A **P-Editor:** Xu ZH

**Figure Legends**

图表

描述已自动生成

**Figure 1** **Survival rate comparison.** A and B:Kaplan-Meier overall survival (OS) curves (A) and progression-free survival (PFS) curves (B) in different subgroups of hepatocellular carcinoma (HCC) patients with circulating tumor cell programmed death-ligand 1 (+); C and D:Kaplan-Meier OS curves (A) and PFS curves (B) in different subgroups of HCC patients with neutrophil-to-lymphocyte ratio; E and F: OS curves (A) as well as PFS curves (B) for different subgroups of HCC patients with circulating tumor cell-neutrophil-to-lymphocyte ratio. HR: Hazard ratio; CTC: Circulating tumor cell; PD-L1: Programmed death-ligand 1; NLR: Neutrophil-to-lymphocyte ratio.



**Figure 2 Comparison of the area under the time-dependent receiver operating characteristic curve for overall survival prediction.** A-C: Comparison of predictive efficacy of circulating tumor cell (CTC)-neutrophil-to-lymphocyte ratio (A), CTC programmed death-ligand 1 (+) (B), and alpha-fetoprotein (C) indicators at 6, 12, and 18 months in hepatocellular carcinoma patients. CTC: Circulating tumor cell; PD-L1: Programmed death-ligand 1; NLR: Neutrophil-to-lymphocyte ratio; AFP: Alpha-fetoprotein; AUC: Area under the curve.

**Table 1 Clinical characteristics of the hepatocellular carcinoma patients in the study**

|  |  |  |
| --- | --- | --- |
| **Variable** | ***n*** | **%** |
| Patients | 124 | 100.0 |
| Sex |  |  |
| Male | 112 | 90.3 |
| Female | 12 | 9.7 |
| Age (years) |  |  |
| < 60 | 73 | 58.9 |
| ≥ 60 | 51 | 41.1 |
| HBV |  |  |
| Negative | 54 | 43.5 |
| Positive | 70 | 56.5 |
| Smoke |  |  |
| Negative | 62 | 50.0 |
| Positive | 62 | 50.0 |
| Alcohol |  |  |
| Negative | 71 | 57.3 |
| Positive | 53 | 42.7 |
| Hypertension |  |  |
| Negative | 94 | 75.8 |
| Positive | 30 | 24.2 |
| Diabetes mellitus |  |  |
| Negative | 107 | 86.3 |
| Positive | 17 | 13.7 |
| Liver cirrhosis |  |  |
| Negative | 78 | 62.9 |
| Positive | 46 | 37.1 |
| Child-Pugh class |  |  |
| A | 65 | 52.4 |
| B | 59 | 47.6 |
| BCLC stage |  |  |
| B | 9 | 7.3 |
| C | 115 | 92.7 |
| ALBI grade |  |  |
| 1 | 64 | 51.6 |
| 2 | 55 | 44.4 |
| 3 | 5 | 4.0 |
| Serum AFP, ng/mL |  |  |
| < 400 | 75 | 60.5 |
| ≥ 400 | 49 | 39.5 |
| Number of tumors |  |  |
| < 2 | 38 | 30.6 |
| ≥ 2 | 86 | 69.4 |
| Tumor diameter, cm |  |  |
| < 5 | 49 | 39.5 |
| ≥ 5 | 75 | 60.5 |
| PVTT |  |  |
| Negative | 69 | 55.6 |
| Positive | 55 | 44.4 |
| Lymph node metastasis |  |  |
| Negative | 43 | 34.7 |
| Positive | 81 | 65.3 |
| Extrahepatic metastases |  |  |
| Negative | 85 | 68.5 |
| Positive | 39 | 31.5 |

HBV: Hepatitis B virus; BCLC: Barcelona clinic liver cancer; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; NLR: Neutrophil-lymphocyte ratio; CTC: Circulating tumor cell.

**Table 2 The correlation between circulating tumor cell PD-L1 (+) and neutrophil-lymphocyte ratio with clinical variables**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **CTC PD-L1 (+) ≤ 1, *n* = 68** | **CTC PD-L1 (+) > 1, *n* = 56** | ***P* value** | **NLR ≤ 3.89, *n* = 67** | **NLR > 3.89, *n* = 57** | ***P* value** |
| Sex |  |  | 0.798 |  |  | 0.768 |
| Male | 61 | 51 |  | 61 | 51 |  |
| Female | 7 | 5 |  | 6 | 6 |  |
| Age (yr) |  |  | 0.705 |  |  | 0.569 |
| < 60 | 39 | 34 |  | 41 | 32 |  |
| ≥ 60 | 29 | 22 |  | 26 | 25 |  |
| HBV |  |  | 0.218 |  |  | 0.765 |
| Negative | 33 | 21 |  | 30 | 24 |  |
| Positive | 35 | 35 |  | 37 | 33 |  |
| Smoke |  |  | 0.470 |  |  | 0.207 |
| Negative | 36 | 26 |  | 37 | 25 |  |
| Positive | 32 | 30 |  | 30 | 32 |  |
| Alcohol |  |  | 0.264 |  |  | 0.337 |
| Negative | 42 | 29 |  | 41 | 30 |  |
| Positive | 26 | 27 |  | 26 | 27 |  |
| Hypertension |  |  | 0.849 |  |  | 0.739 |
| Negative | 52 | 42 |  | 50 | 44 |  |
| Positive | 16 | 14 |  | 17 | 13 |  |
| Diabetes mellitus |  |  | 0.866 |  |  | 0.535 |
| Negative | 59 | 48 |  | 59 | 48 |  |
| Positive | 9 | 8 |  | 8 | 9 |  |
| Liver cirrhosis |  |  | 0.020 |  |  | 0.011 |
| Negative | 49 | 29 |  | 49 | 29 |  |
| Positive | 19 | 27 |  | 18 | 28 |  |
| Child-Pugh class |  |  | 0.898 |  |  | 0.751 |
| A | 36 | 29 |  | 36 | 29 |  |
| B | 32 | 27 |  | 31 | 28 |  |
| BCLC stage |  |  | 0.459 |  |  | 0.430 |
| B | 6 | 3 |  | 6 | 3 |  |
| C | 62 | 53 |  | 61 | 54 |  |
| ALBI grade |  |  | 0.214 |  |  | 0.612 |
| 1 | 38 | 26 |  | 37 | 27 |  |
| 2 | 29 | 26 |  | 28 | 27 |  |
| 3 | 1 | 4 |  | 2 | 3 |  |
| Serum AFP, ng/mL |  |  | 0.153 |  |  | 0.017 |
| < 400 | 45 | 30 |  | 47 | 28 |  |
| ≥ 400 | 23 | 26 |  | 20 | 29 |  |
| Number of tumors |  |  | 0.472 |  |  | 0.549 |
| < 2 | 19 | 19 |  | 19 | 19 |  |
| ≥ 2 | 49 | 37 |  | 48 | 38 |  |
| Tumor diameter, cm |  |  | 0.490 |  |  | 0.847 |
| < 5 | 25 | 24 |  | 27 | 22 |  |
| ≥ 5 | 43 | 32 |  | 40 | 35 |  |
| PVTT |  |  | 0.432 |  |  | 0.038 |
| Negative | 40 | 29 |  | 43 | 26 |  |
| Positive | 28 | 27 |  | 24 | 31 |  |
| Lymph node metastasis |  |  | 0.359 |  |  | 0.929 |
| Negative | 26 | 17 |  | 23 | 20 |  |
| Positive | 42 | 39 |  | 44 | 37 |  |
| Extrahepatic metastases |  |  | 0.590 |  |  | 0.454 |
| Negative | 48 | 37 |  | 44 | 41 |  |
| Positive | 20 | 19 |  | 23 | 16 |  |

HBV: Hepatitis B virus; BCLC: Barcelona clinic liver cancer; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; NLR: Neutrophil-lymphocyte ratio; CTC: Circulating tumor cell.

**Table 3 The correlation between circulating tumor cell-neutrophil-lymphocyte ratio score and clinical baseline characteristics in hepatocellular carcinoma patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **CTC-NLR** | | | ***P* value** |
| **Score 0, *n* = 54** | **Score 1, *n*=27** | **Score 2, *n* = 43** |
| Sex |  |  |  | 0.005 |
| Male | 51 | 20 | 41 |  |
| Female | 3 | 7 | 2 |  |
| Age (yr) |  |  |  | 0.993 |
| < 60 | 32 | 16 | 25 |  |
| ≥ 60 | 22 | 11 | 18 |  |
| HBV |  |  |  | 0.577 |
| Negative | 25 | 13 | 16 |  |
| Positive | 29 | 14 | 27 |  |
| Smoke |  |  |  | 0.152 |
| Negative | 28 | 17 | 17 |  |
| Positive | 26 | 10 | 26 |  |
| Alcohol |  |  |  | 0.022 |
| Negative | 31 | 21 | 19 |  |
| Positive | 23 | 6 | 24 |  |
| Hypertension |  |  |  | 0.451 |
| Negative | 42 | 18 | 34 |  |
| Positive | 12 | 9 | 9 |  |
| Diabetes mellitus |  |  |  | 0.811 |
| Negative | 47 | 24 | 36 |  |
| Positive | 7 | 3 | 7 |  |
| Liver cirrhosis |  |  |  | 0.007 |
| Negative | 39 | 20 | 19 |  |
| Positive | 15 | 7 | 24 |  |
| Child–Pugh class |  |  |  | 0.693 |
| A | 28 | 16 | 21 |  |
| B | 26 | 11 | 22 |  |
| BCLC stage |  |  |  | 0.685 |
| B | 5 | 2 | 2 |  |
| C | 49 | 25 | 41 |  |
| ALBI grade |  |  |  | 0.630 |
| 1 | 30 | 15 | 19 |  |
| 2 | 23 | 11 | 21 |  |
| 3 | 1 | 1 | 3 |  |
| Serum AFP, ng/mL |  |  |  | 0.097 |
| < 400 | 38 | 16 | 21 |  |
| ≥ 400 | 16 | 11 | 22 |  |
| Number of tumors |  |  |  | 0.407 |
| < 2 | 16 | 6 | 16 |  |
| ≥ 2 | 38 | 21 | 27 |  |
| Tumor diameter, cm |  |  |  | 0.915 |
| < 5 | 21 | 10 | 18 |  |
| ≥ 5 | 33 | 17 | 25 |  |
| PVTT |  |  |  | 0.269 |
| Negative | 34 | 15 | 20 |  |
| Positive | 20 | 12 | 23 |  |
| Lymph node metastasis |  |  |  | 0.215 |
| Negative | 18 | 13 | 12 |  |
| Positive | 36 | 14 | 31 |  |
| Extrahepatic metastases |  |  |  | 0.493 |
| Negative | 38 | 16 | 31 |  |
| Positive | 16 | 11 | 12 |  |

HBV: Hepatitis B virus; BCLC: Barcelona clinic liver cancer; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; NLR: Neutrophil-lymphocyte ratio; CTC: Circulating tumor cell.

**Table 4 Univariate Cox regression analysis based on overall survival**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **HR** | **Univariate Cox regression, 95%CI** | ***P* value** |
| Male sex | 0.784 | 0.282-2.182 | 0.641 |
| Age ≥ 60 yr | 0.967 | 0.553-1.692 | 0.907 |
| HBV (positive) | 1.091 | 0.621-1.917 | 0.763 |
| Smoke (positive) | 1.341 | 0.767-2.342 | 0.303 |
| Alcohol (positive) | 1.373 | 0.785-2.402 | 0.267 |
| Hypertension (positive) | 0.711 | 0.364-1.388 | 0.317 |
| Diabetes mellitus (positive) | 0.526 | 0.189-1.461 | 0.218 |
| Liver cirrhosis (positive) | 2.283 | 1.305-3.996 | 0.004 |
| Child-Pugh class (A-B) | 1.619 | 0.919-2.853 | 0.095 |
| BCLC stage (B-C) | 2.063 | 0.501-8.499 | 0.316 |
| ALBI grade |  |  | 0.026 |
| 1 |  |  |  |
| 2 | 1.589 | 0.889-2.842 | 0.118 |
| 3 | 4.111 | 1.394-12.126 | 0.010 |
| AFP ≥ 400 ng/mL | 2.697 | 1.535-4.740 | 0.001 |
| Number of tumors ≥ 2 | 1.243 | 0.670-2.307 | 0.490 |
| Tumor diameter ≥ 5 cm | 1.016 | 0.576-1.793 | 0.957 |
| PVTT (positive) | 1.737 | 0.992-3.042 | 0.053 |
| Lymph node metastasis (positive) | 1.695 | 0.911-3.154 | 0.095 |
| Extrahepatic metastases (positive) | 1.202 | 0.669-2.159 | 0.539 |
| CTC PD-L1 (+) > 1 | 6.657 | 3.590-12.345 | < 0.001 |
| NLR > 3.89 | 3.841 | 2.136-6.908 | < 0.001 |
| CTC-NLR |  |  | < 0.001 |
| 0 |  |  |  |
| 1 | 2.748 | 1.229-6.145 | 0.014 |
| 2 | 9.720 | 4.679-20.192 | 0.000 |

HBV: Hepatitis B virus; BCLC: Barcelona clinic liver cancer; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; NLR: Neutrophil-lymphocyte ratio; CTC: Circulating tumor cell; HR: Hazard ratio; 95%CI: 95% confidence interval.

**Table 5 Multivariate Cox regression analysis based on overall survival**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **HR** | **Overall survival, 95%CI** | ***P* value** |
| Model 1 |  |  |  |
| NLR > 3.89 | 1.603 | 0.789-3.257 | 0.192 |
| CTC PD-L1 (+) > 1 | 5.381 | 2.581-11.215 | < 0.001 |
| Liver cirrhosis (positive) | 1.251 | 0.693-2.258 | 0.457 |
| ALBI grade |  |  | 0.347 |
| 1 |  |  |  |
| 2 | 1.149 | 0.631-2.095 | 0.649 |
| 3 | 2.352 | 0.743-7.442 | 0.146 |
| AFP ≥ 400ng/mL | 2.410 | 1.323-4.390 | 0.004 |
| Model 2 |  |  |  |
| CTC-NLR |  |  | < 0.001 |
| 0 |  |  |  |
| 1 | 2.684 | 1.187-6.070 | 0.018 |
| 2 | 8.470 | 3.957-18.129 | 0.000 |
| Liver cirrhosis (positive) | 1.261 | 0.697-2.282 | 0.442 |
| ALBI grade |  |  | 0.218 |
| 1 |  |  |  |
| 2 | 1.191 | 0.653-2.171 | 0.569 |
| 3 | 2.739 | 0.884-8.489 | 0.081 |
| AFP ≥ 400ng/mL | 2.096 | 1.180-3.723 | 0.012 |

NLR: Neutrophil-lymphocyte ratio; CTC: Circulating tumor cell; ALBI: Albumin–bilirubin; AFP: Alpha-fetoprotein; HR: Hazard ratio; 95%CI: 95% confidence interval.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**